This detailed PDF document provides a comprehensive overview of Imatinib Tablets IP 400 mg and their pivotal role in the treatment of various cancers, particularly Chronic Myeloid Leukemia (CML) and other Philadelphia chromosome-positive malignancies. Imatinib is a targeted therapy known as a tyrosine kinase inhibitor (TKI), specifically developed to inhibit abnormal proteins responsible for cancer cell growth. Approved for use in multiple oncologic indications, Imatinib Tablets IP 400 mg have transformed cancer treatment outcomes, especially in CML patients, by directly targeting the BCR-ABL fusion protein. This targeted mechanism not only improves treatment efficacy but also reduces damage to healthy cells, offering better tolerability than traditional chemotherapy.